BR112021022757A2 - Anticorpo anti-cldn e composição farmacêutica do mesmo e método de detecção para o mesmo - Google Patents

Anticorpo anti-cldn e composição farmacêutica do mesmo e método de detecção para o mesmo

Info

Publication number
BR112021022757A2
BR112021022757A2 BR112021022757A BR112021022757A BR112021022757A2 BR 112021022757 A2 BR112021022757 A2 BR 112021022757A2 BR 112021022757 A BR112021022757 A BR 112021022757A BR 112021022757 A BR112021022757 A BR 112021022757A BR 112021022757 A2 BR112021022757 A2 BR 112021022757A2
Authority
BR
Brazil
Prior art keywords
antibody
pharmaceutical composition
seq
nos
detection method
Prior art date
Application number
BR112021022757A
Other languages
English (en)
Inventor
Han Zheng
Houcong Jin
Qin Pan
Xiangdong Qu
Yejie Du
Original Assignee
Qure Biotechnology Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qure Biotechnology Shanghai Co Ltd filed Critical Qure Biotechnology Shanghai Co Ltd
Publication of BR112021022757A2 publication Critical patent/BR112021022757A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Abstract

anticorpo anti-cldn e composição farmacêutica do mesmo e método de detecção para o mesmo. são fornecidos um anticorpo anti-cldn18.2 e uma composição farmacêutica do mesmo e um método de detecção do mesmo, em que a cadeia pesada do anticorpo é selecionada a partir de qualquer uma dentre seq id nos: 1-7 ou seq id nos: 15-30, e a cadeia leve do anticorpo é selecionada a partir de qualquer uma dentre seq id nos: 8-14 ou seq id nos: 31-46. a capacidade do anticorpo de se ligar a linhas celulares e a células de tecido tumoral é mais poderosa do que a do anticorpo existente imab362, e o efeito antitumoral do anticorpo também é mais poderoso do que o do anticorpo existente imab362.
BR112021022757A 2019-05-16 2020-04-07 Anticorpo anti-cldn e composição farmacêutica do mesmo e método de detecção para o mesmo BR112021022757A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910410255.8A CN111944048B (zh) 2019-05-16 2019-05-16 抗cldn抗体及其药物组合物和检测方法
PCT/CN2020/083570 WO2020228447A1 (zh) 2019-05-16 2020-04-07 抗cldn抗体及其药物组合物和检测方法

Publications (1)

Publication Number Publication Date
BR112021022757A2 true BR112021022757A2 (pt) 2022-02-15

Family

ID=73290063

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021022757A BR112021022757A2 (pt) 2019-05-16 2020-04-07 Anticorpo anti-cldn e composição farmacêutica do mesmo e método de detecção para o mesmo

Country Status (7)

Country Link
US (1) US20220235128A1 (pt)
EP (1) EP3971207A4 (pt)
JP (1) JP7249696B2 (pt)
KR (1) KR20220010002A (pt)
CN (3) CN117264059A (pt)
BR (1) BR112021022757A2 (pt)
WO (1) WO2020228447A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202108398YA (en) 2019-02-01 2021-08-30 Novarock Biotherapeutics Ltd Anti-claudin 18 antibodies and methods of use thereof
CN113637082A (zh) * 2020-04-27 2021-11-12 启愈生物技术(上海)有限公司 一种靶向人claudin和人PDL1蛋白的双特异抗体及其应用
CA3200465A1 (en) * 2020-11-30 2022-06-02 Xiwu HUI Anti-cldn18.2 antibody, drug conjugate, and preparation method therefor and use thereof
CN114634566B (zh) * 2020-12-16 2023-09-19 广州百暨基因科技有限公司 一种抗Claudin18_2的抗原结合片段、抗体及其应用
US20240092892A1 (en) * 2020-12-30 2024-03-21 Bio-Thera Solutions, Ltd. Anti-cldn18.2 antibody, and preparation method therefor and use thereof
CN112940124B (zh) * 2021-04-14 2022-04-05 南京凯地医疗技术有限公司 靶向Claudin18.2的人源化单克隆抗体及其制备方法和应用
CN114181311B (zh) * 2021-12-20 2023-06-20 华东师范大学 一种全人源抗DLL3 scFv及其在CART细胞治疗中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1790664A1 (en) * 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
WO2013167153A1 (en) * 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
WO2013174404A1 (en) * 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014127785A1 (en) * 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014146672A1 (en) 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2015069794A2 (en) * 2013-11-06 2015-05-14 Stem Centrx, Inc. Novel anti-claudin antibodies and methods of use
WO2016165762A1 (en) * 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Drug conjugates comprising antibodies against claudin 18.2
EP3395834A4 (en) * 2015-12-24 2019-10-23 XDCExplorer (Shanghai) Co., Ltd. ANTI-TPBG ANTIBODIES AND ITS PREPARATION METHOD, CONJUGATED AND USE THEREOF
WO2018026742A1 (en) * 2016-08-01 2018-02-08 Askgene Pharma Inc. Novel antibody-albumin-drug conjugates (aadc) and methods for using them
WO2018054484A1 (en) * 2016-09-23 2018-03-29 Biontech Ag Bispecific trivalent antibodies binding to claudin 6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases
CN113321738A (zh) * 2020-02-27 2021-08-31 启愈生物技术(上海)有限公司 肿瘤靶向、抗cd3和t细胞激活三功能融合蛋白及其应用

Also Published As

Publication number Publication date
KR20220010002A (ko) 2022-01-25
JP7249696B2 (ja) 2023-03-31
CN117264059A (zh) 2023-12-22
EP3971207A4 (en) 2023-09-06
WO2020228447A1 (zh) 2020-11-19
EP3971207A1 (en) 2022-03-23
CN117659190A (zh) 2024-03-08
CN111944048B (zh) 2023-10-03
US20220235128A1 (en) 2022-07-28
CN111944048A (zh) 2020-11-17
JP2022532784A (ja) 2022-07-19

Similar Documents

Publication Publication Date Title
BR112021022757A2 (pt) Anticorpo anti-cldn e composição farmacêutica do mesmo e método de detecção para o mesmo
CY1120471T1 (el) Αντισωματα κατα του cd70
BR112015019066A2 (pt) Anticorpos humanos para proteína f do vírus respiratório sincicial e métodos de uso dos mesmos
CL2019000760A1 (es) Tratamiento de migraña refractaria
BR112018003535A2 (pt) receptor de antígeno quimérico, vetor de expressão, composição farmacêutica, e, uso de um vetor de expressão
BR112012032991A8 (pt) camundongo expressando uma imunoglobulina de cadeia leve híbrida.
BR112016025009A2 (pt) anticorpos humanos para a síndrome respiratória do oriente médio - proteína de superfície
UA113712C2 (xx) Антитіло до fap і способи його застосування
EA201592074A1 (ru) Композиции и способы изменения сигнальной системы вторичного мессенджера
SV2011003880A (es) Anticuerpos humanos de alta afinidad para el receptor il-4 humano
CL2012001627A1 (es) Compuestos derivados de 1,3-tiazol-fenilaminopirimidinas, inhibidores de syk; composición farmacéutica; y su uso para el tratamiento de la artritis reumatoide y cancer.
CL2012002433A1 (es) Anticuerpo aislado o fragmento inmunoreactivo del mismo que comprende un dominio variable que se une específicamente a un dominio extracelular del receptor b7-h3; ácido nucleico que lo codifica; hibridoma que lo secreta; reactivo de redireccionamiento de doble afinidad (dart) que lo comprende; composición farmacéutica que lo comprende; y su uso para tratar cáncer.
BR112012023660A2 (pt) novos métodos para direcionar células-tronco cancerosas
BR112015012316A2 (pt) composições coletoras mistas
BR112012025517A2 (pt) ____________________________________________________________ anticorpo que reconhece fator inibidor de leucemia (lif) humano e uso de anti-lif anticorpos no tratamento de doenças associadas a proliferação celular não desejada
PE20140673A1 (es) Nuevos moduladores y metodos para su uso
BRPI0814971A8 (pt) Proteína
BR112018011270A2 (pt) anticorpo isolado, composição farmacêutica, e, métodos para tratamento ou redução da taxa de recorrência de um câncer em um paciente e para detecção de células tronco do câncer.
BR112014004543A2 (pt) método de síntese de proteínas
WO2009019367A3 (fr) Procede de dosage de l'apolipoproteine ai pour le diagnostic in vitro du cancer colorectal
BR112012021326A2 (pt) anticorpo monoclonal anti-vegf completamente humano, método de preparação e uso do mesmo.
BR112018004717A2 (pt) ?composição?
BR112017011642A2 (pt) composto, sal farmaceuticamente aceitável, e, método para tratamento de uma doença ou condição que se beneficia de um aumento em nad+.
BR112018072511A2 (pt) métodos para selecionar uma cepa bacteriana e para profilaxia, inibição e/ou tratamento de uma alergia, cepa, e, composição antialérgica
BR112021020617A2 (pt) Composições probióticas e usos das mesmas